Isaac Thomas, MD
Cardiology · Gurnee, ILNPI 1083662894
Payments from drug & device makers
Across 512 payments — averaging $113.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$46K
- Angiodynamics, Inc.$1K
- Amgen$1K
- Johnson & Johnson$1K
- Novartis$959
- E.r. Squibb & Sons, L.L.C.$829
- plus $7K from 31 others
Across 446 payments — averaging $1161.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$518K
What the payments were for
- Consulting fees$35,27874%
- Travel & lodging$9102%
- Food & beverage$11,15223%
- Education$2811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $45,766 |
| Angiodynamics, Inc. | 4 | $1,401 |
| Amgen | 63 | $1,172 |
| Johnson & Johnson | 54 | $1,063 |
| Novartis | 70 | $959 |
| E.r. Squibb & Sons, L.L.C. | 39 | $829 |
| Merck | 40 | $769 |
| Pfizer | 30 | $731 |
| Boehringer Ingelheim | 31 | $710 |
| Boston Scientific | 16 | $606 |
| AstraZeneca | 33 | $573 |
| Abbott | 9 | $545 |
| Bayer | 18 | $496 |
| Alnylam Pharmaceuticals Inc. | 14 | $428 |
| Lantheus Medical Imaging, Inc. | 3 | $350 |
| Lexicon Pharmaceuticals, Inc. | 10 | $330 |
| Edwards Lifesciences | 4 | $191 |
| Astellas Pharma US Inc | 5 | $165 |
| Regeneron Healthcare Solutions, Inc. | 6 | $138 |
| Impulse Dynamics (USA) Inc. | 5 | $130 |
| Actelion Pharmaceuticals US, Inc. | 4 | $127 |
| Esperion Therapeutics, Inc. | 7 | $105 |
| Novo Nordisk | 3 | $74 |
| Biotronik Inc. | 2 | $71 |
| Inspire Medical Systems, Inc. | 2 | $58 |
| Amryt Pharma Holdings Ltd | 3 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Recor Medical Inc | 2 | $43 |
| Akcea Therapeutics, Inc. | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| CSL Behring | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Cranial Technologies, Inc | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Definity$251
- Watchman$236
- MitraClip$162
- CardioMEMS HF System$148
- SAPIEN 3 Ultra RESILIA$129
- Adempas$125
- Inpefa$124
- ONPATTRO$121
- Repatha$118
- Mitra Clip system$110
How this compares
$58,109 in reported general payments places this provider in the 95th percentile of 26 cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 99 | $140,321 |
| EliquisApixaban | 89 | $97,386 |
| JardianceEmpagliflozin | 69 | $95,991 |
| EntrestoSacubitril/Valsartan | 66 | $88,761 |
| XareltoRivaroxaban | 37 | $48,837 |
| VascepaIcosapent Ethyl | 49 | $36,358 |
| OzempicSemaglutide | 25 | $28,051 |
| Praluent PenAlirocumab | 18 | $24,956 |
| FarxigaDapagliflozin Propanediol | 25 | $22,832 |
| Icosapent Ethyl | 25 | $10,941 |
| Rosuvastatin Calcium | 168 | $2,878 |
| Metoprolol Succinate | 182 | $2,594 |
| Carvedilol | 205 | $2,091 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 117 | $1,787 |
| Ranolazine ErRanolazine | 17 | $1,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $731 | $97,38689 claims |
| Boehringer IngelheimJardiance | $710 | $95,99169 claims |
| NovartisEntresto | $959 | $88,76166 claims |
| Johnson & JohnsonXarelto | $1,063 | $48,83737 claims |
| Novo NordiskOzempic | $74 | $28,05125 claims |
| AstraZenecaFarxiga | $573 | $22,83225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 cardiology providers in Illinois.
Other cardiology in Gurnee
- Raymond ChowGurnee$15K
- Ahmed HashimGurnee$6K
- V ReddyWatseka$14K
- Bohdan FedirkoChicago$10K
- Cesar YuMt Vernon$5K
- Robert AndinaChicago$5K
- James FairbairnChicago$3K
- Priya KansalChicago$0
- Leon FrazinChicago$0
- Michael WingoChampaign$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.